Largest borrow rate increases among liquid names » 08:4507/0207/02/20
MARK, APT, AMC, BCLI, BGS, YCBD, TTNP, PEI, CRC, GRPN
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Remark Media (MARK) 190.24% +3.93, Alpha Pro Tech (APT) 57.24% +2.22, AMC Entertainment (AMC) 71.31% +1.92, BrainStorm (BCLI) 70.30% +1.90, B&G Foods (BGS) 12.82% +1.82, cbdMD (YCBD) 24.11% +1.24, Titan Pharmaceuticals (TTNP) 37.01% +0.62, Pennsylvania REIT (PEI) 86.36% +0.49, California Resources (CRC) 270.47% +0.37, and Groupon (GRPN) 0.68% +0.33.
BrainStorm completes all dosing in Phase 3 pivotal trial of NurOwn in ALS » 06:5107/0207/02/20
BrainStorm announced that…
BrainStorm announced that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn in amyotrophic lateral sclerosis, or ALS. BrainStorm said in a release, "The trial enrolled approximately 200 participants, randomized 1:1 to receive three doses of MSC-NTF cells or placebo, administered over four months. As previously reported, the Company expects top-line data from the trial to be available in the fourth quarter of 2020, consistent with the timeline established upon trial enrollment."
BrainStorm to hold a KOL conference call » 16:3107/0107/01/20
Management holds a Key…
Management holds a Key Opinion Leader conference call to discuss the Company's Alzheimer's Disease Clinical Program on July 8 at 8:15 am. Webcast Link
Largest borrow rate increases among liquid names » 08:4507/0107/01/20
FCEL, VAL, BGS, BCLI, CBL, WPG, SLNO, SKT, MAC, LAKE
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: FuelCell (FCEL) 42.70% +5.69, Valaris Plc (VAL) 123.49% +4.11, B&G Foods (BGS) 34.71% +4.05, BrainStorm (BCLI) 41.08% +2.31, CBL & Associates (CBL) 19.67% +2.18, Washington Prime (WPG) 64.65% +1.65, Soleno Therapeutics (SLNO) 4.04% +1.60, Tanger Factory (SKT) 17.78% +1.54, Macerich (MAC) 14.59% +1.54, and Lakeland Industries (LAKE) 21.94% +1.20.
|Over a week ago|
Largest borrow rate increases among liquid names » 08:4506/2406/24/20
NKLA, ACB, CLIR, SRNE, ATNM, TXMD, NEPT, BBBY, CEMI, BCLI
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: (NKLA) 962.76% +4.10, Aurora Cannabis (ACB) 68.78% +2.13, ClearSign Combustion (CLIR) 97.37% +1.79, Sorrento Therapeutics (SRNE) 135.42% +0.91, Actinium Pharmaceuticals (ATNM) 3.47% +0.68, TherapeuticsMD (TXMD) 21.21% +0.64, Neptune Technologies (NEPT) 50.80% +0.53, Bed Bath & Beyond (BBBY) 6.42% +0.47, Chembio Diagnostics (CEMI) 3.39% +0.40, and BrainStorm (BCLI) 11.12% +0.40.
BrainStorm announces new focused on development of NurOwn » 07:0606/2406/24/20
BrainStorm Cell Therapeutics announced a new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease. As part of the newly announced program, the company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.
BrainStorm granted SME status by EMA » 09:0106/1506/15/20
BrainStorm Cell Therapeutics announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency's Micro, Small and Medium-Sized Enterprise office. The newly granted SME status allows BrainStorm to participate in significant financial incentives that include a 90% to 100% EMA fee reduction for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities as well as fee waivers for selective EMA pre and post-authorization regulatory filings, including Orphan Drug and PRIME designations. Brainstorm is also eligible to obtain EMA certification of quality and manufacturing data prior to review of clinical data. Other incentives include EMA-provided translational services of all regulatory documents required for market authorization, further reducing the financial burden of the market authorization process.
BrainStorm awarded $500K for ALS biomarker research study by the ALS Association » 06:0406/0906/09/20
The ALS Association and I…
The ALS Association and I AM ALS announced that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics to support an amyotrophic lateral sclerosis, or ALS, biomarker research study. The ALS Association said in a release, "The grant will be used to draw insights from data and samples collected from patients enrolled in BrainStorm's ongoing phase 3 clinical trial of its NurOwn treatment, to further understanding of critical biomarkers associated with treatment response for people with ALS. The study is designed to evaluate how NurOwn interacts with its targets in the brain and spinal cord and to explore the changes in the biomarkers that may correlate with response to the drug treatment. Biomarkers are any measurable substance in the body that change over time, such as cholesterol or blood pressure, and that correlate with disease processes or treatment response. If successful, this study will help confirm that the ALS treatment NurOwn works in the way it is intended and will help inform our larger understanding of ALS biomarkers. The joint award to BrainStorm consists of a $400,000 grant from The ALS Association and a $100,000 grant from I AM ALS. As part of this agreement, BrainStorm has agreed to share data and samples with the ALS community so that the results can be independently validated and to advance other ALS research."
|Over a month ago|
BrainStorm announces NurOwn Phase 3 pivotal trial remains on track » 06:0606/0206/02/20
BrainStorm Cell Therapeutics announced an update on the Company's Phase 3 pivotal trial investigating NurOwn in ALS. BrainStorm said in a release, "The Company continues to expect that top-line data from the trial will be announced by Q4-2020, despite the ongoing COVID-19 pandemic that has delayed hundreds of other clinical trials around the world. Due to the importance of the clinical trial and the recognized high unmet need in ALS, Brainstorm and the 6 prestigious U.S. clinical sites have been able to continue treatment visits throughout the COVID-19 pandemic with only occasional scheduling changes to treatments. The decision to continue the trial is also shared by the ALS community and the FDA. The clinical trial sites are at University of California, Irvine; Cedars-Sinai Medical Center; California Pacific Medical Center; Massachusetts General Hospital; University of Massachusetts Medical School and Mayo Clinic. Importantly, the trial's primary outcome measurement is fully validated for telephonic administration, which allowed non-treatment visits to be conducted remotely and to be aligned with protocol assessment timelines. This allows for ongoing high-quality data collection while prioritizing safety of patients and clinical trial site staff."
BrainStorm reports Q1 EPS (32c), consensus (22c) » 07:0605/0705/07/20
Cash, cash equivalents,…
Cash, cash equivalents, and short-term bank deposits were approximately $14.5M at March 31, vs. $6.2M at March 31, 2019. "While many companies have been greatly hindered by the COVID-19 pandemic, (...) the Phase 3 ALS trial remains on track for a Q4'20 topline data readout. Participants in the fully enrolled clinical trial in our 6 United States medical centers of excellence continue to receive their scheduled treatments with the necessary safety protocols in place," stated CEO Chaim Lebovits. "We were able to advance our global footprint by signing an agreement with a senior, leading EMEA regulatory consultant who will advise us as we approach EMEA Regulatory Institutions to present data for NurOwn in ALS, and the advancement of NurOwn in other disease indications".